Medical Countermeasures Surveillance Integrated Program Team
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OS
|
NIAID
|
2012
|
|
Microbiological Testing of Live Biotherapeutic Products
|
Resource Development
|
FDA
|
NIAID
|
2015
|
|
Microphysiological Systems for Drug Efficacy and Toxicity Testing
|
Research Initiative
|
FDA
|
NCATS, NCI, NEI, NHLBI, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIGMS, NINDS, NINR, OD/ DPCPSI, OD/ DPCPSI/ ORWH
|
2012
|
|
Microsystems Team
|
Committee, Advisory Group, or Work Group
|
FDA
|
NIDDK, NINDS
|
2011
|
|
mPOWER mHealth Group
|
Research Initiative
|
CDC, CMS, FDA, HRSA, IHS
|
CIT, FIC, NCCIH, NCI, NEI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NINR, NLM, OD/ DPCPSI/ OBSSR
|
2011
|
|
Multi-Agency Tissue Engineering Science (MATES) Interagency Working Group
|
Committee, Advisory Group, or Work Group
|
ACL, CMS, FDA
|
NCI, NHLBI, NIA, NIAMS, NIBIB, NICHD, NIDCD, NIDCR, NINDS
|
2000
|
|
Muscular Dystrophy Coordinating Committee (MDCC)
|
Committee, Advisory Group, or Work Group
|
ACL, CDC, FDA, HRSA
|
NHLBI, NIAMS, NICHD, NINDS
|
2002
|
|